Molecular targets in meningococci: Efficient routine characterization and optimal outbreak investigation in conjunction with routine surveillance of the meningococcal group B vaccine candidate, fHBP

Clinical and Vaccine Immunology

Volumn 18, Issue 2, 2011, Pages 194-202

  Lucidarme, Jay ^a   Newbold, Lynne S ^a   Findlow, Jamie ^a   Gilchrist, Stefanie ^a   Gray, Stephen J ^a   Carr, Anthony D ^a   Hewitt, James ^a   Kaczmarski, Edward B ^a   Borrow, Ray ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FACTOR H BINDING PROTEIN; MENINGOCOCCUS VACCINE; PORIN A; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL GENE; EPIDEMIC MENINGITIS; FETA GENE; GENE SEQUENCE; GENOTYPE; MOLECULAR TYPING; MULTILOCUS SEQUENCE TYPING; NEISSERIA MENINGITIDIS; NEISSERIACEAE; NONHUMAN; PORB GENE; PRIORITY JOURNAL;

BACTERIAL CAPSULES; BACTERIAL TYPING TECHNIQUES; DISEASE OUTBREAKS; DNA, BACTERIAL; GENOTYPE; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MOLECULAR TYPING; NEISSERIA MENINGITIDIS; SENTINEL SURVEILLANCE; VACCINES, CONJUGATE;

EID: 79551479526     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00401-10     Document Type: Article

References (37)

1. Birtles, A., et al. 2005. Multilocus sequence typing of Neisseria meningitidis directly from clinical samples and application of the method to the investigation of meningococcal disease case clusters. J. Clin. Microbiol. 43:6007-6014.
2. Brehony, C., K. A. Jolley, and M. C. Maiden. 2007. Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol. Rev. 31:15-26.
3. Buckee, C. O., S. Gupta, P. Kriz, M. C. Maiden, and K. A. Jolley. 2010. Long-term evolution of antigen repertoires among carried meningococci. Proc. Biol. Sci. 277:1635-1641.
4. Cartwright, K., S. Reilly, D. White, and J. Stuart. 1992. Early treatment with parenteral penicillin in meningococcal disease. BMJ 305:143-147.
5. EU-IBIS. May 2007. EUIBIS N. meningitidis EQA. http://www.euibis.org/ documents/emgm-07-pdfs/eqa-af.pdf. Health Protection Agency, London, United Kingdom.
6. Feil, E. J., M. C. Maiden, M. Achtman, and B. G. Spratt. 1999. The relative contributions of recombination and mutation to the divergence of clones of Neisseria meningitidis. Mol. Biol. Evol. 16:1496-1502.
7. Fletcher, L. D., et al. 2004. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun. 72:2088-2100.
8. Fox, A. J., M. K. Taha, and U. Vogel. 2007. Standardized nonculture techniques recommended for European reference laboratories. FEMS Microbiol. Rev. 31:84-88.
9. Frasch, C. E., W. D. Zollinger, and J. T. Poolman. 1985. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev. Infect. Dis. 7:504-510.
10. Giuliani, M. M., et al. 2006. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. U. S. A. 103:10834-10839.
11. Gray, S. J., et al. 2006. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J. Med. Microbiol. 55:887-896.
12. Grundmann, H., S. Hori, and G. Tanner. 2001. Determining confidence intervals when measuring genetic diversity and the discriminatory abilities of typing methods for microorganisms. J. Clin. Microbiol. 39:4190-4192.
13. Harrison, L. H., C. L. Trotter, and M. E. Ramsay. 2009. Global epidemiology of meningococcal disease. Vaccine 27(Suppl. 2):B51-B63.
14. Hunter, P. R., and M. A. Gaston. 1988. Numerical index of the discriminatory ability of typing systems: an application of Simpson's index of diversity. J. Clin. Microbiol. 26:2465-2466.
15. Jolley, K. A., C. Brehony, and M. C. Maiden. 2007. Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol. Rev. 31:89-96.
16. Reference deleted.
17. Lucidarme, J., et al. 2009. Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J. Clin. Microbiol. 47:3577-3585.
18. Lucidarme, J., et al. 2010. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin. Vaccine Immunol. 17: 919-929.
19. Madico, G., et al. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 177:501-510. (Pubitemid 43939163)
20. Maiden, M. C., et al. 1998. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc. Natl. Acad. Sci. U. S. A. 95:3140-3145.
21. Maiden, M. C., and I. M. Feavers. 1994. Meningococcal typing. J. Med. Microbiol. 40:157-158.
22. Masignani, V., et al. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197:789-799.
23. Pace, D., A. J. Pollard, and N. E. Messonier. 2009. Quadrivalent meningococcal conjugate vaccines. Vaccine 27(Suppl. 2):B30-B41.
24. Pillai, S., et al. 2005. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine 23:2206-2209.
25. Rosenstein, N. E., B. A. Perkins, D. S. Stephens, T. Popovic, and J. M. Hughes. 2001. Meningococcal disease. N. Engl. J. Med. 344:1378-1388.
26. Schneider, M. C., et al. 2006. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol. 176:7566-7575.
27. Shigematsu, M., K. L. Davison, A. Charlett, and N. S. Crowcroft. 2002. National enhanced surveillance of meningococcal disease in England, Wales and Northern Ireland, January 1999-June 2001. Epidemiol. Infect. 129:459-470.
28. Simpson, E. H. 1949. Measurement of diversity. Nature 163:688.
29. Tettelin, H., et al. 2000. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287:1809-1815. (Pubitemid 30143964)
30. Thompson, E. A., I. M. Feavers, and M. C. Maiden. 2003. Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 149:1849-1858.
31. Urwin, R. 2001. Nucleotide sequencing of antigen genes of Neisseria meningitidis, p. 157-172. In A. J. Pollard and M. C. J. Maiden (ed.), Meningococcal disease: methods and protocols. Humana Press, Totowa, NJ.
32. Urwin, R., et al. 2004. Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect. Immun. 72: 5955-5962.
33. van Belkum, A., et al. 2007. Guidelines for the validation and application of typing methods for use in bacterial epidemiology. Clin. Microbiol. Infect. 13(Suppl. 3):1-46.
34. Vedros, N. A. 1987. Development of meningococcal serogroups, p. 33-37. In N. A. Vedros (ed.), Evolution of meningococcal disease. CRC Press Inc., Boca Raton, FL.
35. Wyle, F. A., et al. 1972. Immunologic response of man to group B meningococcal polysaccharide vaccines. J. Infect. Dis. 126:514-521.
36. Zapata, G. A., W. F. Vann, Y. Rubinstein, and C. E. Frasch. 1992. Identification of variable region differences in Neisseria meningitidis class 3 protein sequences among five group B serotypes. Mol. Microbiol. 6:3493-3499.
37. Zollinger, W. D., et al. 2008. Programme Abstr. 16th Int. Pathog. Neisseria Conf., abstr. O41. Rotterdam, Netherlands, 7 to 12 September.